Regulation of microRNAs function by circular RNAs in human cancer. by Han, Chao et al.
UCLA
UCLA Previously Published Works
Title
Regulation of microRNAs function by circular RNAs in human cancer.
Permalink
https://escholarship.org/uc/item/31n105s5
Journal
Oncotarget, 8(38)
ISSN
1949-2553
Authors
Han, Chao
Seebacher, Nicole A
Hornicek, Francis J
et al.
Publication Date
2017-09-01
DOI
10.18632/oncotarget.19930
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Oncotarget64622www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 38), pp: 64622-64637
Regulation of microRNAs function by circular RNAs in human 
cancer
Chao Han1,2, Nicole A. Seebacher2, Francis J. Hornicek2, Quancheng Kan1 and 
Zhenfeng Duan1,2
1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, P.R. China
2Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and 
Harvard Medical School, Boston, MA, USA 
Correspondence to: Quancheng Kan, email: quanchengkan@yeah.net 
Zhenfeng Duan, email: zduan@mgh.harvard.edu
Keywords: circRNA, miRNA, cancer, gene regulatory mechanisms, target therapy
Received: May 25, 2017    Accepted: July 25, 2017    Published: August 04, 2017
Copyright: Han et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Circular RNAs (circRNAs) are a newly validated class of endogenous non-coding 
RNA, generated from the ligation of exons, introns, or both, which arise via a diverse 
number of cellular mechanisms. Due to rapid advances in the development of combined 
high-throughput sequencing and bioinformatics analyzing tools, many circRNAs have 
recently been discovered, revealing an expansive number of ubiquitously expressed 
mammalian circRNAs. Interestingly, it has recently been confirmed that circRNAs bind 
to microRNAs (miRs), as miR “sponges”, acting to suppress miR function. As miRs 
are known to alter the development and progression of cancer, circRNAs may offer a 
novel diagnostic and prognostic biomarker for cancer. Indeed, recent evidence has 
shown that circRNAs are associated with many human cancers. Herein, we review the 
molecular characteristics and biogenesis of circRNAs, with a focus on newly identified 
circRNAs that may play an important role in human cancer, through their regulation 
of miR expression.
INTRODUCTION
Circular RNAs (circRNAs) have recently been 
identified as naturally occurring alternative RNA splicing 
products, which can inhibit the expression of microRNAs 
(miRs) in eukaryotic cells [1–4]. These miRs are small 
non-coding RNAs that bind to the 3ʹ-untranslated regions 
(3ʹ-UTR) of target messenger RNAs (mRNAs), which 
functions to repress their translation, thereby potentially 
regulating an extensive set of biological processes [5]. 
Emerging evidence has demonstrated that circRNAs are 
closely associated with a number of human diseases, most 
notably, cancer [6, 7]. The mechanisms of miRs expression 
control can occur at the epigenetic, transcriptional, and 
post-transcriptional level [8–10]. Inhibition of miR 
activity by antisense oligonucleotides or antagomirs has 
been used to study the functions of miRs, both in vitro 
and in vivo [11, 12]. Recently, it was found that circRNAs 
can serve as competitive inhibitors by binding to miRs, 
referred to as “miR sponges”, or they may act as target 
mimics to block the activity of a specific miR [2, 4, 13, 
14]. The circRNAs contain binding sites for the miR 
either in the non-coding transcript or in the 3ʹ- UTR of 
a specific gene [15]. High throughput RNA sequencing 
and bioinformatic data analysis have predicted thousands 
of circRNAs in the human genome, suggesting that they 
may function as important post-transcriptional regulators 
[4, 16, 17]. Indeed, the down-regulation of miR expression 
by circRNAs, particularly their role as miR sponges, has 
recently been investigated in numerous different human 
cancers, such as lung, gastric, and colorectal cancers 
[18, 19]. Collectively, this data has brought to light a novel 
suppressive role for circRNAs in miR expression and, 
consequently, altered activity of their downstream target 
genes [20, 21]. Herein, we review the characterization, 
biogenesis and classification of circRNA, with a special 
focus on recent studies which have explored the regulation 
of miR expression by circRNA in human cancer. 
                                                                      Review
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IDENTIFICATION AND CHARACTERIZATION 
OF circRNAS
CircRNAs were initially described as a naturally 
occurring family of non-coding RNAs, ubiquitously 
expressed in mammalian cells [22]. Soon after, researchers 
began to demonstrate that some of these circRNAs could 
in fact be translated [23]. One recent example of this is 
circ-ZNF609, which contains an open reading frame 
spanning from the start codon and ending at an in-frame 
STOP codon, similar to the linear transcript, but formed 
by circularization. It is translated into a protein in a cap-
independent and splicing-dependent manner, becoming 
an example of a protein-coding circRNA in eukaryotes, 
which functions in myogenesis [24]. Recently, it has been 
shown that the expression of circRNAs is widespread, 
with circRNA expression accounting for greater than 
10% of gene expression [25–27]. Compared with linear 
RNA, such as mRNA or long non-coding RNA (lncRNA), 
circRNAs are circular in nature. This single-stranded 
covalently-closed circular structure was first revealed in 
1976 in plant viroids, which are small pathogens known 
to exert similar biological functions to viruses [28]. 
This was closely followed in 1979 by the identification 
of circRNAs in the cytoplasm of eukaryotic cells, and 
in 1991 the first report human circRNA was published 
[29, 30]. These species had generally been considered to 
be of very low abundance and were likely representing 
errors in splicing [25]. It was over a decade later before 
it was revealed that a large number of circRNAs may 
actually exist. So far, there is no evidence to suggest 
that circRNAs are translated, even though most overlap 
protein-coding sequences [26]. 
The synthesis of circRNAs is mostly thought to 
occur by forming a covalent 3ʹ,5ʹ-phosphodiester bond 
from alternative back-splicing of exons and/or introns 
in precursor messenger RNA (pre-mRNA) [22, 31, 32]. 
As a consequence of this, the most prominent difference 
between circRNAs and linear RNAs is that circRNAs do 
not have a 5ʹ cap and a 3ʹ polyadenylated tail structure 
[22]. Based on their specific structure, circRNAs are much 
more stable than their linear counterparts; consequently, 
they are not degraded easily by Ribonuclease R (RNase 
R) or RNA exonuclease activity [25, 33]. Indeed, most 
circRNA species exhibit a half-life of over 48 hours, 
compared to an average half-life of 10 hours for mRNAs 
[22].
A recent study of human circRNAs has revealed 
that these molecules are usually composed of 1–5 exons 
and unlike miRs or lncRNAs that are approximately 22 
and 200 nucleotides (nt) in length, respectively [5, 13]. 
Human circRNAs generally vary in length from less than 
100 nt to over 4000 nt [34]. As a consequence of this 
diversity in length and structure, circRNAs are likely to 
have an expansive and complex range of mechanisms and 
biological functions, most of which are yet to be identified. 
Moreover, circRNAs have also shown variability in 
cellular localization, which may be linked to their 
functional mechanisms. Notably, circRNAs which have 
sponge activity have been consistently localized to the 
cytoplasm [25, 35]. 
In addition to this, cross-species comparisons 
using genome-wide analyses have shown that sites of 
circularization are conserved across species at a rate above 
that expected by chance [3, 35]. Furthermore, circRNAs 
also demonstrate tissue and developmental stage-specific 
expression [36]. This, in turn, suggests that circRNAs 
may have specific physiological roles within cells. Several 
possible functions have been proposed, including miR 
binding, miR transport, protein binding, regulation of 
protein transcription and translation [2, 25, 37]. 
THE BIOGENESIS AND CLASSIFICATION 
OF circRNAS
Most circRNAs are produced from host genes and 
contain complete exons [23]. The biogenesis of circRNAs 
involves pre-mRNA transcription by RNA polymerase II 
(RNA pol II), and back-splicing mediated by spliceosomal 
machinery [27, 38]. Recent studies have indicated that 
the biogenesis of circRNAs, through the back-splicing 
of pre-mRNA, requires different mechanisms than 
those used for the canonical splicing of linear RNAs 
[27, 39]. There are four proposed circularization models 
for circRNAs synthesis (Figure 1) [39, 40]. The first 
model of circRNAs synthesis is intron-pairing-driven 
circularization, termed “direct back-splicing” (Figure 1A). 
It has been suggested that intronic motifs might border 
circularized exons and upon joining, via base pairing, 
they form the fused circRNA. It has been proposed that 
these bordering intronic sequences are generally very long 
(~15,000 nt) and are almost perfectly complementary, 
which is commonly referred to as reverse complementary 
matches (RCMs). Consequently, this promotes the hairpin 
formation of the transcript [41]. This helps to explain how 
the two tails of the pre-mRNA can be in spatial proximity, 
prior to splicing. Notably, it has been reported that in 
humans the bordering introns of circRNAs are highly 
enriched in ALU repeats, which contain RCMs [25]. 
More recent studies have further verified the model of 
intron-pairing-driven circularization [17, 33, 41, 42]. The 
second model of circRNA synthesis is termed the lariat-
driven circularization or exon skipping model (Figure 1B) 
[39]. In an exon skipping event, a 3ʹ splice donor (SD) 
site of an upstream exon covalently joins to the 5ʹ splice 
acceptor (SA) of a downstream exon, thereby forming a 
lariat structure. This lariat may then be internally spliced, 
and the intronic sequences deleted or preserved. This leads 
to the generation of either exon circRNAs (ecircRNAs) 
or exon-intron circRNAs (EIciRNAs) [43, 44]. The third 
model of circRNAs synthesis is termed the RNA binding 
protein (RBP) driven circularization model (Figure 1C). 
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In this model, the alternative splicing factors, Quaking 
(QKI) and Muscleblind (MBL), bind certain circRNA 
flanking introns and act as RBPs to bring two flanking 
intronic sequences close together, inducing circularization 
of genes that contain binding sites for RBPs in their 
introns [45]. This mechanism is similar to the intron-
pairing-driven circularization pathway, except that RBPs 
regulate adjacent splice sites instead of the direct base 
pairing between complementary motifs seen in the intron-
pairing-driven model. In addition to this, binding of RBPs 
may also promote circularization by inhibiting canonical 
splicing or by stabilizing complementary sequences 
[38, 45]. The fourth model of circRNAs synthesis is 
spliceosome-mediated machinery driven circularization 
(Figure 1D). In this model, stable circular intronic RNAs 
(ciRNAs) result when intron lariats escape the normal 
intron debranching and degeneration [46]. The process 
depends on the presence of a 7 nt GU-rich motif near the 
5ʹ splice site and a 11 nt C-rich motifs near the branchpoint 
site [46, 47]. 
Figure 1: The four potential mechanisms of circRNAs biogenesis. In the nucleus of a eukaryocytic cell, precursor messenger 
RNA (pre-mRNA) is firstly transcribed from DNA by RNA polymerase II (RNA Pol II). Following this, circRNAs are formed through the 
non-canonical splicing of this pre-mRNA. (A) Intron-pairing-driven circularization. Two connected introns form a circular structure via 
base-pairing. Introns are then either eliminated or retained to form exon circular RNA (ecircRNA) or exon-intron circular RNA (EIciRNA). 
(B) Lariat-driven circularization. Exon skipping occurs when a splice donor (SD) site in the 3ʹ end of exon 1 covalently links to a splice 
acceptor (SA) site in the 5ʹ end of exon 4. This forms a lariat structure containing exon 2 and exon 3. CircRNAs and linear RNAs are formed 
once introns are removed. (C) RBP-driven circularization. Binding of RBPs (blue box) creates a bridge between two flanking introns. The 
circRNA is then formed after introns are removed. (D) Circular intron RNA (ciNRA). The intron-derived circRNAs form when intron 
lariats escape the usual intron debranching and degeneration processes, and thus form stable circular intronic RNAs (ciRNAs) Sequences 
near the 5-splice site (blue box), which is rich in “GU” sequences, and the branch point (green box), which is rich in “C” residues, allow for 
an intron to escape debranching, generating the ciRNA. CircRNAs are generally located in the cytoplasm and are relatively stable owing 
to their resistance to RNA exonucleases.
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FUNCTION OF circRNAS AS SPONGES OF 
mirs IN HUMAN CANCER
One of the most important functions ascribed to 
circRNAs is their ability to bind to miRs as a competing 
endogenous RNAs (ceRNAs), thereby repressing the 
function of the miRs (Figure 2) [15, 25, 39]. Indeed, 
circRNAs have been shown to have multiple miR 
response elements (MREs) [2]. For instance, in one study 
of CDR1as/ciRS-7, a circRNA sponge for miR-7 over 60 
conserved seed match segments were identified, suggesting 
very dense binding [2, 48]. Due to the growing interest 
in this field, the cellular functions of sponge miRs are 
currently being investigated [20, 21]. Interestingly, reports 
have suggested that depending on the cellular localization 
of circRNAs, they may have different functional roles. 
For example, in the nucleus, circRNAs can form large 
RNA-protein complexes (RPCs) through their binding to 
RNA binding proteins (RBPs), which will influence the 
transcription of local linear RNA [49–51]. CircRNAs can 
also function in gene regulation by competing with linear 
pre-mRNA splicing. For instance, circMbl has the capacity 
to sponge muscleblind (MBL), by regulating the splicing 
of its own pre-mRNA into a circMbl or translatable mRNA 
[38]. While the multitude of potential functions exhibited 
by circRNA remains to be fully elucidated, circRNAs are 
known to participate in a plethora of biological processes. 
To date, all known circRNAs displaying sponge activity 
have been localized to the cytoplasm, which may be an 
important feature in their functional role (Figure 2) [15].
CircRNA also have been shown to be associated 
with several diseases, most notably cancer [20, 52–54]. At 
present, it is known that there exists a specific association 
pattern between circRNAs and miRs in cancer [18, 19]. 
Current evidence suggests that circRNAs may enhance or 
suppress the progression of cancer through suppressing 
miR species that are associated with proliferation, 
differentiation, migration and carcinogenesis [27].
CircRNAs in lung cancer
The circRNA, circRNA-ITCH (cir-ITCH), has 
been reported to play an important role in inhibiting lung 
cancer progression, by functioning as an miR sponge 
of mulitple oncogenic miRs. This acts to enhance the 
expression of E3 ubiquitin-protein ligase (ITCH) and thus 
suppress activation of Wnt/β-catenin signaling, which is 
an important pathway involved in the process of cellular 
proliferation and migration. Cir-ITCH has been verified to 
bind with many different miRs, including, miR-7, miR-
17, miR-214, miR-128, and miR-216b [2, 14, 55]. In one 
study, the expression level of cir-ITCH was determined in 
cancer tissues and paired adjacent noncancerous tissues 
of 78 lung cancer patients [56]. The results showed that 
the expression of cir-ITCH was significantly decreased 
in approximately 73% of the lung cancer tissues [56]. 
To investigate the interaction between cir-ITCH and the 
miRs, miR-7 and miR-214, the human lung cancer cell 
lines A549 and NCI-H460 were cotransfected with cir-
ITCH plasmid and a constructed luciferase reporter of 
miR-7 or miR-214, and then the luciferase activity was 
detected. In both cell lines transfected with empty vector 
(control of cir-ITCH plasmid), luciferase activity was 
significantly decreased, in a concentration dependent 
manner, by a miR-7 or miR-214 mimic. However, no 
significance change in luciferase activity with the miR 
mimics occurred in cells with cir-ITCH hyper-expression. 
Thus, these results indicate that in lung cancer cells cir-
ITCH can inhibit miR-7 and miR-214 through binding 
them as sponge [56]. 
In another study of non-small cell lung cancer 
(NSCLC) tissues from 101 patients, circRNA_100876 
(circ-CER) was shown to be significantly upregulated 
compared to paired adjacent non-tumorous tissues [57]. 
Among the assessed clinicopathological parameters, there 
was a significant association between higher expression of 
circ-CER and both regional lymph node involvement and 
advanced tumor stage. Notably, the overall survival time 
of NSCLC patients with elevated circ-CER expression 
was significantly shorter than those patients with lower 
circ-CER expression [57]. Further research findings 
indicated that the circ-CER might be involved in tumor 
cell growth, progression and metastasis in NSCLC [58]. 
Therefore, circ-CER may prove to be a useful diagnostic 
marker and potential therapeutic target for the treatment of 
NSCLC in human patients [57].
CircRNAs in hepatocellular carcinoma
There is increasing evidence linking circRNAs to 
the development of hepatocellular carcinoma (HCC). In 
an analysis of integrated high-throughput data, a number 
of circRNAs were shown to be linked to overexpression 
of miR-181a-3p, an inhibitor of the enzyme O(6)-
Methylguanine-DNA methyltransferase (MGMT), 
which is known to be involved in DNA damage, thereby 
indicating a link between circRNAs and the progression 
of HCC through miR regulation [59]. In a more recent 
and extensive study, circRNA microarray detection was 
applied to both HCC tissues and adjacent normal tissues, 
identifying 61 differentially expressed circRNAs [60]. Of 
the three that were further confirmed by qRT-PCR, hsa_
circ_0005075 demonstrated significant association with 
some clinicopathological factors of HCC patients [60]. 
Gene ontology and pathway analysis of hsa_circ_0005075 
revealed that there was a strong relationship between this 
circRNA and cell adhesion, which is an important part of 
cancer cell proliferation and metastasis [60]. Moreover, 
larger sized HCC tumors showed greater levels of hsa_
circ_0005075 expression, indicating that hsa_circ_0005075 
may promote tumor growth. Therefore, hsa_circ_0005075 
may have the potential to be a promising biomarker for 
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HCC [60]. Based on the predictive program Arraystar 
(DNASTAR, Madison, WI, USA), which performs 
sequence variation analysis, four miRs, including miR-23b-
5p, miR-93-3p, miR-581, and miR-23a-5p were identified 
as having binding sites within hsa_circ_0005075 [60]. 
Analysis of the hsa_circ_0005075 circRNA-miR-mRNA 
interaction network indicated that miR-23b-5p exhibited 
the largest interaction network [60]. Interestingly, miR-
23b-5p has been shown to be downregulated in both gastric 
cancer and adenocarcinoma of the esophagus [61, 62]. It 
has been speculated that hsa_circ_0005075 acts as an miR 
sponge, suppressing the expression of miR-23b-5p in cancer 
[60]. While a high level of hsa_circ_0005075 expression in 
HCC tissues has been speculated to correlate with tumor 
progression, as mentioned above, the detailed molecular 
mechanisms by which hsa_circ_0005075 functions as a miR 
sponge to regulate the circRNA-miR-mRNA network in the 
process of HCC development needs further investigation. 
Another circRNA, hsa_circ_0001649, has also 
shown decreased expression in HCC tissues compared 
with matched adjacent liver tissues [63]. Following the 
knockdown of hsa_circ_0001649 with siRNA, there was 
an increase in the expression level of the pro-metastatic 
matrix metalloproteinases (MPPs), MMP9, MMP10 and 
MMP13 [63]. This indicates that hsa_circ_0001649 is 
negatively correlated with the metastasis of HCC and may 
therefore also have the potential for use as a biomarker for 
diagnosing HCC [63].
Figure 2: CircRNAs acting as miR sponges can indirectly regulate target genes of miR. In the nucleus, miR genes are 
transcribed by RNA pol II to generate primary miR (pri-miR). These pri-miRs are then processed into precursor miRs (pre-miRs) and 
transported into the cytoplasm where they form mature miRs. A mature miR can bind to the 3ʹ-UTR of a mRNA, thereby suppressing its 
translation or result in its cleavage. A circRNA may be rich in miR response elements (MREs). As a result of this, circRNA and mRNA 
can compete for the same miR. Therefore, it is likely that circRNAs can indirectly regulate the expression of mRNAs which containing the 
same miR binding sites.
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Circular RNA profiling has also revealed that 
another circRNA, circHIPK3, is upregulated in liver 
cancer [20]. This circHIPK3, which is derived from Exon2 
of the HIPK3 gene, has been reported in high abundance 
within both humans and mice [20]. This highly stable 
circRNA was shown to bind to multiple miRs, including 
a well-known tumor suppressor miR, miR-124, reducing 
its activity [20]. Therefore, targeting circHIPK3 may help 
to reduce patient HCC cell growth, like it has been shown 
in the huh7 hepatocarcinoma and HCT-116 colorectal 
carcinoma cell lines following circRNA silencing [20]. 
In a recent report examining tissue specific and 
developmental-stage-specific expression of human 
circRNAs, one of the examined circRNAs, CDR1as (also 
known as ciRS-7), a non-coding antisense transcript to 
the cerebellar degeneration-related protein 1 (CDR1), 
was identified to contain 63 conserved binding sites for 
miR-7 located within neural tissue, which acted to impair 
midbrain development in zebrafish due to inhibition of 
miR-7 function [2]. Interestingly, ciRS-7 has also been 
shown to be significantly upregulated in HCC tissues 
[64]. When ciRS-7 is knocked-down, there is a significant 
inhibition of HCC cell proliferation and invasion, which 
is likely due to the release of miR-7 [64, 65]. Thus, ciRS-
7 was verified as a miR-7 sponge, acting to fine tune the 
expression of miR-7 targeted genes through an indirect 
regulation pathway.
CircRNAs in gastric cancer
Using RNA-sequencing analysis, 180 circRNAs have 
been found to be differentially expressed in gastric cancer 
tissues compared with normal tissues [66]. Expression of 
the circRNAs, circPVT1, has been shown to be upregulated 
in gastric cancer [66]. A luciferase reporter assay has been 
used to confirm that circPVT1 acts as a sponge of the tumor 
suppressor miR-125 family, and also indirectly regulates the 
expression of the transcription factor, E2F2, which plays a 
crucial role in the control of the cell cycle and action of 
tumor suppressor proteins [66]. Consequently, the ectopic 
expression of circPVT1 may reduce the antineoplastic 
effects of miR-125b and E2F2. Therefore, circPVT1 has 
the potential to promote colony formation of gastric cancer 
cells via inhibition of miR-125 [66]. 
Another circRNA, hsa_circ_002059, has also been 
confirmed to be downregulated in 101 gastric cancer 
tissues that were compared with paired adjacent non-
cancerous tissues [67]. The decreased expression of hsa_
circ_002059 was notably related with distant metastasis, 
TNM stage, gender and age [67]. Together, these results 
suggest that hsa_circ_002059 may have the potential to be 
a biomarker for the diagnosis and staging of gastric cancer. 
Hsa_circ_0000096, also known as circHIAT1, has 
also been found to be downregulated in gastric cancer 
tissues and gastric cancer cell lines compared with non-
cancerous tissues and normal gastric epithelial cells [68]. 
Moreover, the siRNA knockdown of hsa_circ_0000096 
has been shown to significantly inhibit cell proliferation 
and migration in vitro and in vivo [68]. The knockdown 
of hsa_circ_0000096 also blocked cell cycle progression 
and prevented the transition of cells from the G0/G1 to S 
phase within the gastric cancer cells [68]. Furthermore, 
knockdown of hsa_circ_0000096 in xenograft nude 
mouse models also suppress tumor growth. Generally, it 
is thought that within cancers oncogenes will be highly 
expressed, whereas tumor-suppressor genes are expressed 
at low levels. However, hsa_circ_0000096 appears to be an 
exception to this. This inconsistency may be explained by 
its interaction with miRs. Indeed, databases of circRNA, 
have indicated that hsa_circ_0000096 can interact with 17 
different types of miR. Moreover, qRT-PCR results have 
confirmed that within a number of gastric cancer cell lines 
there was a decrease in miR-224, a CD40 regulator, and an 
increase in miR-200a, which targets E-cadherin, following 
the knockdown of hsa_circ_0000096 [68]. Together, the 
above data indicates that in addition to hsa_circ_002059, 
hsa_circ_0000096 may also be  have a role in the future as 
a  novel biomarker for the diagnosis of gastric cancer [68]. 
circRNAs in colorectal cancer 
As observed in lung cancer, the circRNA, cir-ITCH, 
has also been reported to be significantly down-regulated 
in 45 examined colorectal cancer (CRC) tissues [55]. 
In a study of the CRC cell lines, HCT116 and SW480, 
sponge activity of cir-ITCH was demonstrated towards 
miR-7, miR-20a, and miR-214 [55]. These miRs have 
been shown to downregulate a number of target genes 
that are mostly involved in regulation and execution of 
G1/S transition, including the pro-proliferative target gene 
cyclinD1 [55]. It has also been reported that the ectopic 
expression of cir-ITCH inhibits the expression of c-myc 
and cyclin D1, which are target genes of the Wnt/β-catenin 
signaling pathway [55]. This indicated that cir-ITCH may 
be involved in regulation of the Wnt/β-catenin signaling 
pathway, which is known to be important for the regulation 
of cell proliferation and migration [55]. In line with this, 
studies of cir-ITCH over-expression have demonstrated 
a decrease in cellular proliferation of both HCT116 and 
SW480 cells. Therefore, it is likely that cir-ITCH has an 
anti-proliferative role in HCCs [55]. 
Another circRNAs, hsa_circ_001569, has also been 
shown to highly expression in CRC when compared with 
non-cancerous tissue samples [69–71]. An assessment of 
two public databases (StarBase v2.0 and circBase) and 
three bioinformatic algorithms (TargetScan, Pictar and 
miRANDA) has shown that hsa_circ_001569 contains a 
binding site for miR-145, and that this miR has three target 
genes, E2F5, BAG4 and FMNL2, which it could inhibit 
through 3ʹUTRs promoter binding [1, 71, 72]. Previous 
studies have shown that E2F5 is a transcription factor 
that controls the gene expression of proteins involved in 
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cell cycle control [73], BAG4 has been linked to cancer 
cell aggressiveness [74, 75], and FMNL2 promotes cell 
proliferation, motility, invasion, metastasis and epithelial-
mesenchymal transition [76, 77]. By preventing the 
down-regulation of E2F5/BAG4/FMNL2, by miR-145, 
hsa_circ_001569 has been shown to promote CRC cell 
proliferation and invasion [71]. Subsequent studies have 
indicated that hsa_circ_001569 promotes proliferation by 
increasing the number of cells in the S and G2/M phases 
of the cell cycle [71]. Moreover, knockdown of hsa_
circ_001569 in SW620 and LOVO cells has been shown to 
reverse invasive abilities [71]. However, unlike the other 
circRNAs that have been discussed, hsa_circ_001569 
directly inhibits miR-145 transcriptional activity, rather 
than suppressing its expression [71]. 
Hsa_circ_0000069, which was identified by 
unsupervised hierarchical clustering analysis, also has 
been shown to be dysregulated in CRC [78], with over-
expression identified in CRC tissues. Knockdown of hsa_
circ_0000069 using siRNA, was reported to inhibit cell 
proliferation, migration, and invasion, as well as induce 
G0/G1 phase arrest of cell cycle in HT-29 cells [78]. 
Similarly, CRC tissues have also shown elevated 
levels of circ-BANP [79]. A knockdown of circ-BANP 
using siRNA was also shown to reduce proliferation 
and colony formation of the CRC cell lines, HCT116 
and HT29. Moreover, p-Akt expression was reduced by 
this knockdown, indicating that circ-BANP-induced cell 
proliferation might involve the PI3K-Akt pathway, which 
is well known to be involved in cancer cell survival and 
cell cycle progression [79]. 
The circRNA hsa_circ_001988, has also been 
examined in 31 matched CRC tissues and normal colon 
mucosa [80]. Compared with the normal samples, 
the expression of hsa_circ_001988 was significantly 
downregulated in the CRC cell lines [80]. The results 
also demonstrated a significant correlation between the 
expression level of hsa_circ_001988 and cancer cell 
differentiation and perineural invasion. This is of particular 
importance because perineural invasion is a well-defined 
predictor of CRC patient outcomes and perineural invasion 
is known to be negatively associated with the survival time 
and recurrence of CRC in patients [19, 20]. These results 
indicate that hsa_circ_001988 may represent a potential 
novel biomarker of CRC prognosis [80]. 
Another recent study by Hsaio et al., used differential 
expression analysis of circRNAs in 48 colorectal tumor 
tissues compared to the corresponding adjacent non-tumor 
tissues [81]. The study identified circCCNB, circCDK13, 
and circCCDC66, which is formed from exons 8–10 of 
CCDC66, to be significantly elevated in the CRC tissues 
[81]. CircCCDC66 was selected by the authors for further 
investigation as its parental transcript possessed no known 
function. Interestingly, RT-PCR results from multiple 
cancer cell lines, including: colorectal (Caco-2, HCT116, 
HT-29, LS123), breast (MCF-7, MDA-MB-231, MDA-
MB-468), pancreatic (BxPC-3, MIA PaCa-2) and cervical 
(HeLa) cancer cell lines, demonstrated circCCDC66 
expression, which indicates that this circRNAs may be 
important for tumorigenesis [81]. Functional investigations 
both in vivo and in vitro revealed that circCCDC66 has 
an important role in a diverse number of pathological 
processes, including cell proliferation, migration, invasion, 
and anchorage-independent growth [81]. The study also 
identified 99 potential miRs which have binding sites 
within exons 8–10 of circCCDC66. This suggests that 
circCCDC66 may function as a miR sponge to protect a 
specific proto-oncogene, namely Myc, from miR activity 
in CRC. To confirm this, an in vitro transcription combined 
with in vivo circularization protocol was used to detect the 
sponge effects of circCCDC66. Three miRs (miR-33b, 
miR-93, and miR-185) were predicted to be sponged by 
circCCDC66. Further knockdown studies of circCCDC66 
confirmed that it does function as miR sponge of miR-33b 
and miR-93 in CRC [81]. 
circRNAs in esophageal cancer
Recent studies have uncovered several dysregulated 
circRNAs, including hsa_circ_001059, hsa_circ_000167, 
hsa_circ_0067934, and cir-ITCH, in esophageal squamous 
cell carcinoma (ESCC), which is the seventh most 
common cause of cancer related death in American Men 
[82–84]. In a study by Su et al., which identified over 3700 
human circRNAs, two of these, hsa_circ_001059 and 
hsa_circ_000167, were observed at significantly different 
levels in the human radioresistant esophageal cancer cell 
line KYSE-150R, compared to parental cell line KYSE-
150 [82]. Subsequent circRNAmiR coexpression network 
analysis showed that the above two circRNAs were the 
most important factors in the potential circRNA/miR 
network [82]. These results implicated the abnormally 
expressed circRNAs in the development of radiation 
resistance in the esophageal cancer cells [82]. 
Hsa_circ_0067934, is also markedly overexpressed 
in ESCC tissues and has been correlated with poor 
differentiation, as well the T stage (I-II), and TNM stage 
(I-II) [83]. Moreover, siRNA mediated silencing of 
hsa_circ_0067934 suppressed ESCC cell proliferation, 
migration and cell cycle progression [83]. Other clinical 
factors, such as lymph node metastasis or tumor size 
were not correlated with hsa_circ_0067934 expression. 
Considering that TNM staging is classily used to evaluate 
patient prognosis, whereby higher stages (stage III 
and IV) have a worse prognosis, it is possible that hsa_
circ_0067934 may represent a potential marker of ESCC 
prognosis. 
Cir-ITCH, which acts as tumor suppressor gene in 
lung cancer and CRC has also generally been shown to be 
down-regulated in ESCC, following the analysis of 684 
ESCC and their adjacent noncancerous tissues [84]. The 
authors also identified that cir-ITCH acts as a sponge of 
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miR-7, miR-17, and miR-214, thereby up-regulated the 
target gene ITCH, which negatively regulates the Wnt/β-
catenin pathway via targeting dishevelled (Dvl) protein 
[85]. Importantly, it is known that the Wnt/β-catenin 
pathway has an important role in the carcinogenesis of 
many cancers, such as hepatobiliary cancer, lung cancer, 
breast cancer, and ESCC [86–89]. Collectively, this data 
exemplifies that role of cir-ITCH as a negative regulator 
of the Wnt/β-catenin signaling pathway, acting indirectly 
via sponging of miRs [84]. 
circRNAs in breast cancer
Ductal carcinoma in situ (DCIS) accounts for 
approximately 20% of breast cancers detected by 
mammography [90]. While DCIS is generally considered 
to be highly curable, some women with DCIS will develop 
life-threatening invasive breast cancer, infiltrating ductal 
cancer (IDC), but the determinants of this progression 
remains largely unknown. This may be attributed to the 
same histological subtypes sharing similar gene expression 
patterns [91, 92]. 
An analysis of the expression of circRNAs in 
DCIS/IDC samples from five patients was assessed 
along with an invasive breast cancer cell line, MCF-7, 
using publicly available RNA-seq data and run on the 
bioinformatic detection pipeline, CIRCexplorer [92]. The 
results identified two circRNAs, hsa_circ_0122662 and 
hsa_circ_0001358, in the IDC samples and the MCF-7 
cell line. Five possible miRs (miR-200c-3p, miR-200b-
3p, miR-429, miR-376a-3p, and miR-376b-3p) were 
identified, using the Starbase human Pan cancer tool, 
that could interact with the hsa-circ-0001358 [92]. The 
first three, miR-200c-3p, miR-200b-3p, and miR-429, 
which belong to miR-200 family, could inhibit migration 
and invasion abilities of breast cancer cells [93, 94]. 
Following from this, genes known to participate in 
Epithelial Mesenchymal Transitions (EMT), which were 
known targets of the miR-200 family were examined, 
including ZEB1 (Zinc Finger E-Box Binding Homeobox 
1), ZEB2 (Zinc Finger E-Box Binding Homeobox 
2), VIM (Vimentin), BMI-1 (B lymphoma Mo-MLV 
insertion region 1 homolog), and FN1 (Fibronectin 1) 
[92]. However, no meaningful interactions were identified 
[92]. Interestingly, many circRNAs were found to be 
expressed in either DCIS or IDC, which could represent a 
measurable difference in dynamic expression. Therefore, 
differential circRNA expression may be worthy of further 
investigation, to help with the understanding of the 
molecular mechanisms of DCIS progression to IDC.
Circ-Seq analysis of circRNAs, has confirmed 
that circ-Foxo3 is also downregulated in breast cancer 
cell lines and breast cancer tissues when compared 
with noncancerous cell lines or normal tissues [21]. 
Overexpression of circ-Foxo3 in the breast cancer cell 
line, MDA-MB-231, significantly reduced proliferation 
and cell survival in vitro [95]. In vivo analysis of nude 
mice subcutaneously injected with MDA-MB-231 cells 
transfected with circ-Foxo3 demonstrated that circ-
Foxo3 could inhibit tumor growth [95].  Moreover, 
TUNEL staining of tumor sections revealed that circ-
Foxo3 transfected tumor cells demonstrate extensive 
cell death, suggesting expansive cell apoptosis in the 
tumors. In addition to this, 25 binding sites were detected 
in circ-Foxo3 for eight miRs, including miR-22, miR-
136, miR-138, miR-149, miR-433, miR-762, miR-3614-
5p, and miR-3622b-5p [21]. Transfection of these miRs 
into MDA-MB-231 cells decreased cellular apoptosis. 
Collectively these studies indicate that circ-Foxo3 exerts 
a fundamental biological role as an miR sponge.
circRNAs in genitourinary system cancer 
Bladder cancer is the most prevalent malignant 
tumor of the urinary system and is the 8th most common 
cause of cancer related death in men [96]. In a recent 
study by Zhong et al., high throughput microarray assays 
identified six circRNAs as differentially expressed in 
bladder cancer tissues when compared with paired non-
cancerous tissues [97]. CircTCF25, circZFR, circPTK2, 
and circBC048201 were all significantly up-regulated, 
while circFAM169A and circTRIM24 were both down-
regulated [97]. Bioinformatic analysis found MREs in 
circTCF25 that indicate binding sites for the miRs, miR-
103a-3p and miR-107. DIANA-miRPath analysis revealed 
that both of these miRs are associated with the PI3K-Akt 
signaling pathway, which is frequently perturbed in cancer 
[97]. Further studies revealed that these miRs were also 
expressed at lower levels in the bladder carcinoma tissues 
[97]. Ectopic overexpression of circTCF25 was shown 
to promote proliferation and migration of the bladder 
cancer cells via inhibition of miR-103a-3p and miR-107 
[97]. Previous studies have reported that miR-103a-3p 
and miR-107 can negatively regulate oncogenic factors, 
including CDK6 [98, 99]. Indeed, Western blot analysis of 
the miR sponge, circTCF25, demonstrated an increase in 
the protein level of CDK6. These results illustrate that the 
circTCF25-miR-103a-3p/miR-107-CDK6 network plays 
an important role in bladder cancer [97]. 
In a comprehensive analysis of differentially 
expressed profiles of circRNAs in four bladder carcinoma 
patients, 469 differentially expressed circRNAs were 
identified [100]. Gene Ontology analysis revealed that 
the gene expression profile of the linear counterparts of 
differentially over-expressed circRNAs favored protein 
modification processes, protein binding and cellular protein 
metabolic processes, while downregulated circRNAs 
favored molecular functions and catalytic activity [100]. 
9 circRNAs where identified to have common binding 
sites for miRs, indicating the potential regulation of 
downstream target genes. These circRNAs included; circ-
MYLK and circ-CTDP1, which have MREs for miR-29a-
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3p that targets DNMT3B, ITGB1, VEGFA and HAS3; and 
circ-PC, which has an MRE for miR-185-3p that targets 
ADD1and BAP1 [100]. As these target genes have been 
implicated in cancer cell development and progression, this 
circRNA-miR interaction offers a new perspective for the 
tumorigenesis mechanisms of bladder carcinomas.
In an assessment of clear cell renal cell carcinoma 
(ccRCC) tissues, expression of circRNA of Hippocampus 
Abundant Transcript 1(circHIAT1) was reported to be 
downregulated [101]. Moreover, circHIAT1 expression 
was found to be higher in non-metastatic ccRCC samples 
when compared to the matched metastatic ccRCC 
samples. Furthermore, ccRCC patients with higher 
circHIAT1 expression had a better overall survival rate 
than patients with lower circHIAT1 expression [101]. 
Analysis of circHIAT1 activity revealed direct binding 
to three miRs, miR-195-5p, MiR-29a-3p, and MiR-29c-
3p. Interestingly, in contrast to the classical function of 
circRNAs serving as a “miR sponge”, circHIAT1 acted as 
an “miR reservoir”, increasing miR stability, and thereby 
resulting in reversal of androgen receptor-mediated 
ccRCC migration and invasion. In summary, the process 
of cell migration and invasion in ccRCC cells might be 
suppressed by the circHIAT1-mediated inhibition of miR-
195-5p/29a-3p/29c-3p signaling pathways [101]. 
circRNAs in other cancers
As we have seen, aberrant circRNAs have recently 
been implicated in a number of cancers, including 
lung, hepatic, gastric, colorectal, esophageal, breast 
and genitourinary cancers (Table 1). However, they are 
by no means limited to this set of cancers. In fact, this 
rapidly expanding field of research is bringing to light the 
important roles of circRNAs in many more cancer types.
Approximately 476 differentially expressed 
circRNAs have been revealed in 46 assessed gliomas 
tissues, as compared with control brain tissues [102]. 
Eight circRNAs, including circ_COL1A2, circ_PTN, 
circ_VCAN, circ_SMO, circ_PLOD2, circ_GLIS3, circ_
EPHB4, and circ_CLIP2 showed significantly higher 
expression in glioblastoma (GBM) than in normal tissues 
[102]. It was speculated that these circRNAs will act as 
miR sponges to elevate the expression of genes involved 
in abnormal biological processes. However, this study 
requires future investigations to reveal the circRNA 
regulatory roles in GBM [102]. The circRNAs, cZNF292, 
has also been shown to participate in glioma cell growth 
and tube formation [103]. Silencing of cZNF292 expression 
was reported to inhibit glioma cell proliferation and halt 
cell cycle progression in U87MG and U251 cells via 
inactivation of the Wnt/β-catenin signaling pathway [103]. 
In laryngeal squamous cell cancers (LSCC), two 
circRNAs, hsa_circ_100855 and hsa_circ_104912, 
showed the greatest upregulation and downregulation, 
respectively, among the 698 identified dysregulated 
circRNAs [104]. The high level of hsa_circ_100855 
was shown to correlate with the T3-4 stage, neck nodal 
metastasis and advanced clinical stage of LSCC, while the 
low level of hsa_circ_104912 related to the T3-4 stage, 
neck nodal metastasis, poor differentiation and advanced 
clinical stage. This report highlighted the potential for hsa_
circ_100855 and hsa_circ_104912 as novel biomarkers for 
the diagnosis and progression of LSCCs [104]. 
In pancreatic ductal adenocarcinoma (PDAC), 
the expression profile of circRNAs between PDAC and 
the matched normal tissues identified 351 differentially 
expressed circRNAs by microarray analysis [16]. 
These included 209 up-regulated circRNAs and 142 
down-regulated circRNAs. Among all the differentially 
expressed circRNAs, seven randomly selected circRNAs, 
including two up-regulated circRNAs (hsa_circ_0001946 
and hsa_circ_0005397) and five down-regulated 
circRNAs (hsa_circ_0006913, hsa_circ_0000257, hsa_
circ_0005785, hsa_circ_0041150, and hsa_circ_0008719), 
were examined by qRT-PCR to validate the microarray 
data. Moreover, circRNA-miR interaction analysis 
indicated that hsa_circ_0005785 has the potential capacity 
to bind to miR-181a and miR-181b [16]. Previous studies 
have demonstrated that miR-181a has a vital function 
in promoting pancreatic cancer growth and migration, 
while miR-181b has been associated with the resistance 
of pancreatic cancer cells to gemcitabine [105, 106]. 
This data supports a role for hsa_circ_0005785 in PDAC 
tumorigenesis and/or in mediating PDAC drug resistance. 
An analysis of papillary thyroid cancers (PTC), 
using Arraystar Human circRNA Microarray to 
systematically profile and analyze the expression of 
circular RNAs, has revealed 88 significantly upregulated 
circRNAs and 10 downregulated circRNAs when 
compared to normal thyroid tissues [107]. Based on 
these dysregulated circRNAs and their predicted MREs, 
a network map of circRNA-miR interactions was 
constructed using Cytoscape. One of the downregulated 
circRNAs, hsa_circRNA_100395, showed interactive 
potential with two cancer-related miRs, miR-141-3p and 
miR-200a-3p [107]. This report suggests that the hsa_
circRNA_100395-miR-141-3p/miR-200a-3p axis may 
be involved in the pathogenesis of PTC tumors [107]. 
However, this putative hypothesis is yet to be verified. 
A cluster analysis of oral squamous cell carcinomas 
(OSCC), has identified 280 differentially expressed 
circRNAs, including 139 upregulated circRNAs and 
141 downregulated circRNAs with a two-fold or greater 
change [108]. One of the circRNAs, circRNA_100290, 
was upregulated in OSCC by nearly seven-fold when 
assessed by microarray analysis, and four-fold when 
examined by qRT-PCR, when compared with non-
cancerous matched tissue. Functional analysis found 
that a knockdown of circRNA_100290 could induce 
G1/S arrest in SCC9 cell lines, and this significantly 
inhibited cell proliferation. In accordance with this, si-
Oncotarget64631www.impactjournals.com/oncotarget
Table 1: Identified circRNAs in a range cancers
Name circRNA ID Expression in cancer Cancer Sponge target Function regulated genes/pathways Reference
CDR1as/ciRS-7 hsa_circ_0001946 upregulation liver cancer miR-7 oncogene - 65
hsa_circ_0005075 hsa_circ_0005075 upregulation liver cancer
miR-23b-5p, miR-
93-3p, miR-581, 
miR-23a-5p
biomarker - 60
circPVT1 hsa_circ_0001821 upregulation gastric cancer miR-125a/b
oncongene, 
biomarker
- 66
hsa_circ_001061 hsa_circ_0000069 upregulation colorectal cancer - oncogene - 78
hsa_circ_001569 hsa_circ_0000677 upregulation colorectal cancer miR-145 oncongene - 71
hsa_circ_0067934 hsa_circ_0067934 upregulation esophageal cancer - biomarker - 83
hsa_circ_001059 hsa_circ_0000554 upregulation esophageal cancer
miR-30c-1, miR-
30c-2, miR-122, 
miR-139-3p, miR-
339-5p, miR-1912
- - 82
circTCF25 hsa_circ_0041103 upregulation bladder cancer miR-103a-3p, miR-
107
oncogene, 
biomarker
PI3K-Akt signaling, CDK6, 
proliferation and migration 
97
circHIPK3 hsa_circ_0000284 upregulation liver cancer 
miR-124, miR-
152, miR-193a, 
miR-29a, miR-29b, 
miR-338, miR-379, 
miR-584 and miR-
654
oncogene - 20
circ-BANP - upregulation colorectal cancer - oncogene - 79
circRNA_100876/
circ-CER
hsa_circ_0023404 upregulation lung cancer - biomarker - 57
circCCDC66 hsa_circ_0001313 upregulation
colorectal cancer, 
breast, pancreatic, 
cervical
miR-33b, miR-93
oncogene, 
biomarker
- 81
circRNA_100290 hsa_circ_0013339 upregulation
oral squamous 
cell carcinomas
miR-29 oncogene
G1/S growth cycle arrest, 
differentiation, apoptosis
108
cZNF292 hsa_circ_0004383 unknown glioma - oncogene
Wnt/β-catenin signaling 
pathway, cell cycle 
progression
103
circ-Foxo3 hsa_circ_0006404 downregulation breast cancer
miR-22, miR-136, 
miR-138, miR-149, 
miR-433, miR-762, 
miR-3614–5p, 
miR-3622b–5p
tumor 
suppressor
- 21, 95
CDR1as/ciRS-7 hsa_circ_0001946 downregulation
nervous system 
cancer, liver 
cancer
miR-7, miR-671-
5p, miR-671-3p
biomarker - 54, 64
hsa_circ_001599 hsa_circ_0001649 downregulation
liver cancer, 
gastric cancer
- biomarker - 63
hsa_circ_002059 hsa_circ_0000140 downregulation gastric cancer - biomarker - 67
hsa_circ_001988 hsa_circ_0001451 downregulation colorectal cancer - biomarker - 80
cir-ITCH hsa_circ_0001141 downregulation
colorectal cancer, 
esophageal 
cancer, lung 
cancer
miR-7, miR-17, 
miR-20a, miR-214, 
miR-128, miR-
216b 
tumor 
suppressor
Wnt/β-catenin signaling 
pathway, cell cycle 
progression
55, 56, 84
hsa_circ_000167 hsa_circ_0000518 downregulation esophageal cancer
miR-181a-2, miR-
512-5p, miR-521, 
miR-556-5p, miR-
663b, miR-1204
- - 82
hsa_circ_0005785 hsa_circ_0005785 downregulation pancreatic cancer miR-181a/b -
growth, migration and drug 
resistance 16
circHIAT1 hsa_circ_0000096 downregulation
gastric cancer, 
clear cell renal 
cell carcinoma
miR-195-5p/29a-
3p/29c-3p, miR-
224
biomarker, 
tumor 
suppressor
reversal of androgen 
receptor-mediated ccRCC 
migration and invasion
68, 101
circRNA_100290 decreased tumor growth in vivo nude 
mice models [108]. Cytoscape was used on the hsa_
circRNA_100290-miR-target gene network to visualize 
their interactions based on the circRNA microarray data. 
The Arraystar predictive software listed miR-29b-3p, 
miR-29c-3p and miR-29a-3p as the top three most likely 
miR targets of circRNA_100290. The interaction between 
miR-29b and circRNA_100290 was then confirmed by a 
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luciferase reporter assay. Together, the results indicated 
that circRNA_100290 may be a sponge of the miR-29 
family, which are known to be involved in the regulation 
of cell proliferation, differentiation, and apoptosis [108]. 
In addition to the work on solid tumors, a role for 
circRNAs has also been shown in acute myeloid leukemia 
(AML). In a study of 115 human AML samples, hsa_
circ_0004277 was reported to be downregulated [109]. 
Interestingly, a much lower expression level of hsa_
circ_0004277 was found in newly diagnosed, untreated 
AML patients compared to the healthy controls, while 
patients that achieved complete remission following 
treatment had restored hsa_circ_0004277 expression, 
showing no difference compared to controls. Moreover, 
in the relapsed-refractory patients, downregulated hsa_
circ_0004277 expression was again observed. Analysis of 
the molecular interaction between hsa_circ_0004277 and 
numerous miRs was also predicted, identifying miR-138-
5p, miR-30c-1-3p hsa-miR-892b, hsa-miR-571, and hsa-
miR-328-3p as potential candidates [109]. Downstream 
targets of these miRs, included SH3GL2, PPARGC1A, 
PIP4K2C, SH2B3, ZNF275, and ATP1B4 [109]. The 
mechanisms of which are yet to be established in AML. 
Therefore, it is possible that hsa_circ_0004277 might be a 
useful diagnostic biomarker in AML.  
CONCLUSIONS AND PERSPECTIVES
Since the first discovery of circRNAs, which were 
thought to be errors in RNA splicing, circRNAs are now 
regarded as ubiquitously expressed, abundant, and stable 
class of RNA molecules with a range of activities, including 
sponge, translation, biomarker, and regulation molecules. 
Recently, studies have highlighted the importance of 
circRNA dysregulation in a multitude of human cancers. 
As summarized in this review, circRNAs contribute to 
various biological processes within tumor cells, including 
proliferation, migration, invasion, and apoptosis. CircRNAs 
represent a novel class of diverse endogenous RNAs that 
regulate miR expression through harboring MREs. This 
circRNA-miR interaction can act by regulating downstream 
transcriptional activity of miR target genes. Interestingly, 
many of these miR target genes have been identified 
as oncogenes, indicating the importance of circRNA 
dysregulation in cancer. Previous studies have shown how 
miR expression can be regulated through mechanisms, such 
as DNA copy number variations, epigenetics, transcription 
factors and other mechanisms in cancer. Herein, we have 
reviewed a newly identified mechanism of miR regulation 
by circRNA occurring at the post-transcriptional level. 
Importantly, furthering our understanding of the regulatory 
mechanisms of circRNA on the expression of miRs will 
help provide new insights into cancer-cell development 
and may even prove to be clinically useful diagnostic and 
predictive biomarkers, as well as novel therapeutic targets 
for cancer patients. 
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